Patents Assigned to Instituto Carlos Slim de la Salud, A.C.
-
Patent number: 11840495Abstract: The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.Type: GrantFiled: December 23, 2021Date of Patent: December 12, 2023Assignees: The Broad Institute, Inc., Instituto Carlos Slim de la Salud, A.C., Brigham and Women's Hospital, Inc.Inventors: Brian T. Chamberlain, David Kornfilt, Florence F. Wagner, Maria Alimova, Anna Greka, Joseph Growney
-
Publication number: 20230142508Abstract: Disclosed herein are methods for inducing insulin secretion in a glucose-dependent manner and compounds for use in these methods.Type: ApplicationFiled: November 21, 2022Publication date: May 11, 2023Applicants: The Broad Institute, Inc., The General Hospital Corporation, Instituto Carlos Slim de la Salud, A.C.Inventors: Sean M. Burns, Bridget K. Wagner, Amedeo Vetere
-
Patent number: 11555031Abstract: Disclosed herein are methods for inducing insulin secretion in a glucose-dependent manner and compounds for use in these methods. The compounds may have the structure of formula I(a): wherein the substituents are as described in the description; or a pharmaceutically acceptable form thereof.Type: GrantFiled: March 19, 2018Date of Patent: January 17, 2023Assignees: The Broad Institute, Inc., The General Hospital Corporation, Instituto Carlos Slim de la Salud, A.C.Inventors: Sean M. Burns, Bridget K. Wagner, Amedeo Vetere
-
Patent number: 11492670Abstract: The present invention relates to compositions and methods for targeting cancer-specific DNA sequences, such as copy number amplifications and other types of cancer-specific sequence variations, such as cancer-specific polymorphisms, insertions, or deletions. The present invention provides hereto sequence-specific DNA targeting agents targeting a sequence within the amplified DNA region or a sequence otherwise specific for a cancer cell compared to a non-cancer cell. The invention further relates to methods for treating cancer, comprising administering such sequence-specific DNA targeting agents. The invention further relates to methods for preparing sequence-specific DNA targeting agent, as well as screening methods using the DNA targeting agents.Type: GrantFiled: October 20, 2016Date of Patent: November 8, 2022Assignees: THE BROAD INSTITUTE INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: William C. Hahn, Andrew Aguirre, April Cook, Glenn Cowley, Robin Meyers, David E. Root, Aviad Tsherniak, Barbara Weir, Francisca Vazquez
-
Publication number: 20220133693Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of microsatellite unstable cancers. In particular, the instant disclosure provides for identification of a cancer as exhibiting microsatellite instability (MSI) and/or impaired mismatch repair (MMR), and selection and/or administration of an inhibitor of the WRN helicase as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer.Type: ApplicationFiled: June 3, 2019Publication date: May 5, 2022Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: Francisca Vazquez, Adam Bass, Tsukasa Shibue, Edmond Chan, James McFarland, Mahmoud Ghandi, Aviad Tsherniak
-
Publication number: 20220090083Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of EGLN1-dependent cancers. In particular, the instant disclosure provides for identification of a cancer as EGLN1-dependent, and selection and/or administration of an inhibitor of EGLN1 or VHL (Von Hippel-Lindau Tumor Suppressor) as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer.Type: ApplicationFiled: September 11, 2019Publication date: March 24, 2022Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: William Hahn, Francisca Vazquez, Colles Price
-
Publication number: 20220065864Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers that exhibit elevated expression and/or amplification of the ABCB1 (MDR1) transporter, optionally for reasons related to development of chemotherapeutic resistance having occurred during treatment with an initial chemotherapeutic drug. In particular, the instant disclosure provides for identification of a cancer as possessing elevated ABCB1 expression and/or exhibiting resistance to a non-tepoxalin chemotherapeutic drug, and selecting and/or administering tepoxalin, a tepoxalin derivative and/or metabolite thereof as a therapeutic agent for such a cancer and/or subject having or at risk of developing such a cancer. Methods and compositions for therapies that combine such tepoxalin or tepoxalin-related compounds with other cancer therapies and/or chemotherapeutic agents are also provided.Type: ApplicationFiled: November 8, 2019Publication date: March 3, 2022Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: Steven CORSELLO, Ryan SPANGLER, Rohith NAGARI, Todd GOLUB
-
Publication number: 20220054433Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.Type: ApplicationFiled: October 5, 2021Publication date: February 24, 2022Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., Instituto Carlos Slim de la Salud, A.C.Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney
-
Publication number: 20220023233Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.Type: ApplicationFiled: October 6, 2021Publication date: January 27, 2022Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., Instituto Carlos Slim de la Salud, A.C.Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney
-
Publication number: 20220017524Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of FOXA1 and/or FOXA1 gene targets, such as certain breast, liver and/or prostate cancers, including luminal and/or ER-positive forms of breast cancer. Three previously identified adenosine receptor antagonists, CGS-15943, MRS-1220 and SCH-58261, as well as furan ring moiety-possessing derivatives of CGS-15943 are specifically provided for killing cancer cells in a manner that appears to involve activation of the aryl hydrocarbon receptor (AHR) by such compounds. The instant disclosure therefore provides for selecting and/or administering CGS-15943, MRS-1220, SCH-58261 and/or a furan-possessing derivative of CGS-15943, MRS-1220 and/or SCH-58261 as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer.Type: ApplicationFiled: November 14, 2019Publication date: January 20, 2022Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: Steven CORSELLO, Ryan SPANGLER, Rohith NAGARI, Todd GOLUB, Amael MADEC
-
Publication number: 20220010383Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit arm-level loss of chromosome 16q, focal copy loss of 16q13 and/or low expression of metallothionein proteins, such as certain uterine, ovarian, gastroesophageal and lung cancers. Three known drugs, disulfiram, elesclomol and thiram, as well as certain disulfiram metabolites, are specifically provided for killing cancer cells characterized by arm-level loss of chromosome 16q, focal copy loss of 16q13 and/or low expression of metallothioneins. The instant disclosure therefore provides for selecting and/or administering disulfiram, elesclomol and thiram and/or active metabolites or derivatives of disulfiram, elesclomol and thiram as a therapeutic agent(s) to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.Type: ApplicationFiled: November 13, 2019Publication date: January 13, 2022Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: Steven CORSELLO, Ryan SPANGLER, Rohith NAGARI, Todd GOLUB
-
Publication number: 20220008457Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of cancers, particularly cancers that exhibit elevated expression of SLC26A2, such as certain ovarian, endometrial, brain, bone, and lung cancers, as well as melanoma. A previously identified vanadium-containing compound, bis(maltolato)oxovanadium(IV) (BMOV), specifically provided for killing of SLC26A2 expressing cancer cells in a SLC26A2-dependent manner. The instant disclosure therefore provides for selecting and/or administering BMOV and related vanadium-containing compounds as a therapeutic agent to target a cancer cell and/or subject having or at risk of developing a cancer. Methods and compositions for therapies that include such compounds are also provided.Type: ApplicationFiled: November 13, 2019Publication date: January 13, 2022Applicants: THE BROAD INSTITUTE, INC., DANA-FARBER CANCER INSTITUTE, INC., INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: Steven CORSELLO, Ryan SPANGLER, Rohith NAGARI, Todd GOLUB
-
Publication number: 20210169827Abstract: The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of proteinopathies, particularly MUC1-associated kidney disease (ADTKD-MUC1 or MKD), Retinitis Pigmentosa (e.g., due to rhodopsin mutations), autosomal dominant tubulo-interstitial kidney disease due to UMOD mutation(s) (ADTKD-UMOD), and other forms of toxic proteinopathies resulting from mutant protein accumulation in the ER or other secretory pathway compartments and/or vesicles, among others. The disclosure also identifies and provides TMED9-binding agents as capable of treating or preventing proteinopathies of the secretory pathway, and further provides methods for identifying additional TMED9-binding agents.Type: ApplicationFiled: January 28, 2021Publication date: June 10, 2021Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC., Instituto Carlos Slim de la Salud, A.C.Inventors: Anna Greka, Moran Dvela-Levitt, Maria Alimova, Eric Lander, Todd R. Golub, Florence Wagner, Brian Chamberlain, Valeria Padovano, Joseph Growney
-
Publication number: 20190350938Abstract: The invention features compositions and methods that are useful for increasing the level or activity of SLC16A11 in a subject, there by treating or preventing type 2 diabetes in the subject.Type: ApplicationFiled: June 27, 2017Publication date: November 21, 2019Applicants: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: EITAN HOCH, SUZANNE BETH ROSENBERG JACOBS, VICTOR RUSU, LIPING ZHAO, JOSE M. MERCADER BIGAS
-
Patent number: 10370697Abstract: The present invention provides nucleic acid constructs that encode fusion peptides comprising a bioluminescent protein and a precursor of a secreted peptide or protein expressed at the cell surface and high throughput screening assays using same.Type: GrantFiled: May 19, 2017Date of Patent: August 6, 2019Assignees: THE BROAD INSTITUE, INC., THE GENERAL HOSPITAL CORPORATION, INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: Sean Burns, David Altshuler, Amedeo Vetere
-
Patent number: 10370716Abstract: The present invention features a highly sensitive assay for detecting frameshift mutations for high throughput use. Also provided herein are methods for diagnosing or determining a predisposition for developing medullary cystic kidney disease type 1 (MCKD1) in a subject by detecting a frameshift mutation in the GC-rich variable number of tandem repeats (VNTR) sequence of the mucin 1 gene (MUC-1).Type: GrantFiled: February 10, 2015Date of Patent: August 6, 2019Assignees: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, INSTITUTO CARLOS SLIM DE LA SALUD, A.C.Inventors: Andrew Kirby, Andreas Gnirke, Brendan Blumenstiel, Matthew Defelice, Mark Daly
-
Patent number: 9657329Abstract: The present invention provides nucleic acid constructs that encode fusion peptides comprising a bioluminescent protein and a precursor of a secreted peptide or protein expressed at the cell surface and high throughput screening assays using same.Type: GrantFiled: November 7, 2012Date of Patent: May 23, 2017Assignees: The Broad Institute Inc., The General Hospital Corporation, Instituto Carlos slim de la Salud, A.C.Inventors: Sean Burns, David Altshuler, Amedeo Vetere
-
Patent number: 9370551Abstract: The present invention provides methods related to the treatment of head and neck squamous cell carcinoma (HNSCC) and its associated premalignant lesions. In particular, the invention features methods which may specifically target HNSCC-associated genes and alter gene expression to treat or alleviate a symptom of HNSCC, or its related premalignant lesions. These methods may involve decreasing the function of an HNSCC-associated gene with aberrant gain-of-function; or increasing the function of an HNSCC-associated gene with aberrant loss-of-function.Type: GrantFiled: July 25, 2012Date of Patent: June 21, 2016Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, Massachusetts Eye and Ear Infirmary, Dana-Farber Cancer Institute, Inc., University of Pittsburgh-Of The Commonwealth of Higher Education, Instituto Carlos Slim de la Salud, A.C.Inventors: Le Cong, Ann Marie Egloff, Levi A. Garraway, Jennifer Rubin Grandis, Eric S. Lander, Nicholas Stransky, Aaron D. Tward, Feng Zhang